Medicis Pharmaceutical Corporation

Dermaforce Holdings, LLC

Medicis Pharmaceutical Coropration

Mitchell S Wortzman

Eugene H Gans

Bhiku G Patel

R Todd Plott

Kuljit S Bhatia

Philip J Gordon

Steven B Newhard

Douglas Anthony Bakan

Waranush Jitpraphai

David Watt

Rhoda Narins

Xiaoming Lin

David H McDaniel

Shirishkumar Kulkarni

Jonah Shacknai

Ashish Ashokrao Deshmukh

Sajeev Chandran

Pravin Meghrajji Bhutada

The present disclosure provides a non-autologous product that is a mixture of two or more cells or tissue cultures of fibroblast, or extracts from cultures, or media cultures, isolated from separate individuals, either homogeneous or heterogeneous. The cells or factors are blended together in a product that imparts desired characteristics to the skin of a recipient who is not a source of the mixture. The present disclosure also relates to methods of making and using and/or culturing the fibroblasts including to optimize the potency of the mixture to impart one or more the desired characteristics to the skin of a recipient.

Fibroblast mixtures and methods of making and using the same

The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.

Controlled release pharmaceutical dosage forms

The present disclosure relates to dosage forms and methods that enhance the absorption of minocycline in the gastrointestinal tract and thereby enhance bioavailability of the minocycline, and further provides methods of using these dosage forms for the treatment of conditions such as acne.

Gastroretentive dosage forms for minocycline

An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/&#x2212;0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/&#x2212;0.2% hydroxypropoxylated.

Method for the treatment of acne and certain dosage forms thereof

The present disclosure relates to dosage forms, e.g., swell, float and bioadhesive, and methods that enhance the absorption of doxycycline in the gastrointestinal tract. The oral dosage forms control the spatial and temporal delivery of doxycycline in the gastrointestinal tract. This controlled spatial and temporal delivery provides a site and rate of release, respectively, of the doxycycline into the gastrointestinal tract that enhances the amount of the doxycycline absorbed into the bloodstream.

Gastroretentive dosage forms for doxycycline

Methods for applying injectable fillers are provided. In some embodiments, the methods can extend effectiveness of the injectable filler. In some embodiments, the methods can provide for an elevated level of effectiveness of the injectable filler. In some embodiments, the methods can prolong the effectiveness of the injectable filler.

Method of applying an injectable filler

An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.

Extended-release minocycline dosage forms

Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

Minocycline oral dosage forms for the treatment of acne

The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.

Compositions and methods for enhancing corticosteroid delivery

A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Growing community of inventors

Scottsdale, AZ, United States of America

Mitchell S Wortzman